Stockscreener 앱 받기
149.22
0.31%
0.5296
전일 마감가:
$148.69
열려 있는:
$148.17
하루 거래량:
4.38M
Relative Volume:
0.45
시가총액:
$368.20B
수익:
$65.51B
순이익/손실:
$8.93B
주가수익비율:
42.00
EPS:
3.5532
순현금흐름:
$14.12B
1주 성능:
-1.16%
1개월 성능:
+0.54%
6개월 성능:
+24.68%
1년 성능:
+89.82%
1일 변동 폭
$146.09
$150.36
1주일 범위
$146.09
$152.01
52주 변동 폭
$78.39
$156.92
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
149.24 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,185.60 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.26 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.69 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
145.66 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Merck, Daiichi pull US application for second partnered cancer therapy - Reuters
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years - Benzinga
Merck, Daiichi withdraw ifinatamab FDA application - Mugglehead Investment Magazine
Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading - AD HOC NEWS
Merck stock climbs 2.0 percent ahead of the open - AD HOC NEWS
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
Alpha Buying: Follow the Money From NVIDIA and Merck - Benzinga
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine - Benzinga
What Is Driving the Latest Milestones at Merck & Co. (NYSE:MRK)? - Kalkine Media
Merck's drug for diabetes-related eye disease meets trial goal - Reuters
Merck says remigromig met BRUNELLO vision endpoint, flags eye risks - Mugglehead Investment Magazine
Merck & Co. stock falls 1.86 percent as Q2 sales rise - AD HOC NEWS
Merck's experimental eye drug met its vision goal, but eye bleeding rates were higher than with the other drug - Stock Titan
Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck and Co. stock falls 1.9 percent before the bell - AD HOC NEWS
QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Merck stock falls 2.63 percent at the close - AD HOC NEWS
Merck pipeline seen driving potential re-rating as clinical catalysts approach - Proactive financial news
Merck & Co. stock gains as Japan clears Keytruda injection - AD HOC NEWS
Merck and Co. stock gains 0.94 percent ahead of the open - AD HOC NEWS
Merck stock gains 1.97 percent at the close - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Bought by Andra AP fonden - MarketBeat
MRK|Merck & Co Inc|Price:150.910|Chg%:+1.410 - TradingKey
The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy? - The Motley Fool
Merck & Co. stock falls 36.58 percent year to date - AD HOC NEWS
Merck: Time To Trim, Overvalued, And Overbought (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck & Co Inc Share PriceMRK, RNS News, Articles, Quotes, & Charts (NYSE:MRK) - Proactive financial news
Merck & Co., Inc. (NYSE:MRK) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Could Merck & Co. (NYSE:MRK) Shift the Healthcare Stocks Narrative? - Kalkine Media
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer - Benzinga
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week - Seeking Alpha
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV - Business Wire
Nykredit A S Invests $92.32 Million in Merck & Co., Inc. $MRK - MarketBeat
What Merck is, what it makes, and why it matters in pharma - qz.com
Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise - finance.yahoo.com
Merck & Co Inc's Dividend Analysis - Yahoo Finance
Merck & Company, Inc. (MRK) Stock Analysis: Evaluating A Healthcare Giant's Potential Upside - DirectorsTalk Interviews
Merck & Co., Inc. Target of Unusually Large Options Trading (NYSE:MRK) - MarketBeat
Merck & Co. stock gains as DBS lifts price target and Q2 2026 revenue grows - ad-hoc-news.de
Merck & Co. stock holds after Wall Street Zen cuts rating - ad-hoc-news.de
Merck & Co., Inc. (NYSE:MRK) Lowered to Hold Rating by Wall Street Zen - MarketBeat
7,741 Shares in Merck & Co., Inc. $MRK Bought by Talon Private Wealth LLC - MarketBeat
Merck & Co. stock gains as analysts lift price targets on cancer drug progress - ad-hoc-news.de
The Manufacturers Life Insurance Company Has $266.40 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
IPG Investment Advisors LLC Lowers Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Corient Private Wealth LP - MarketBeat
Rep. Maria Elvira Salazar Buys Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
Merck & Co. stock heads into the open after a 1.9% drop - ad-hoc-news.de
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
1.05%
자본화:
|
볼륨(24시간):